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Abstract
Background: Several lines of evidence support a role for CCL2 (monocyte chemotactic protein-1) and its receptor 
CCR2 in the development of atherosclerosis. The aim of the present study was to determine the association of the 
CCR2 Val64Ile polymorphism with the development of coronary artery disease in the WOSCOPS study sample set.
Findings: A total of 443 cases and 1003 controls from the West of Scotland Coronary Prevention Study (WOSCOPS) 
were genotyped for the Val64Ile polymorphism in the CCR2 gene. Genotype frequencies were compared between 
cases and controls. The CCR2 Val64Ile polymorphism was found not to be associated with coronary events in this study 
population (odds ratio 1.15, 95% CI 0.82-1.61, p = 0.41).
Conclusions: This case-control study does not support an association of the CCR2 Val64Ile polymorphism with 
coronary artery disease in the WOSCOPS sample set and does not confirm a possible protective role for CCR2 Val64Ile 
in the development of coronary artery disease.
Introduction
There is increasing evidence from numerous studies to
indicate that the over-recruitment of leukocytes, espe-
cially monocytes, is central to the pathology of athero-
sclerosis [1-4]. Consequently, atherosclerosis is
considered now to be an inflammatory disease. Chemok-
ines are inflammatory chemotactic cytokines that play a
role in leucocyte recruitment and the chemokine CCL2
(monocyte chemoattractant protein-1 or MCP-1) has
been found to be highly expressed in human atheroscle-
rotic plaques [5]. CCL2 attracts monocytes as well as T
lymphocytes and mediates its effects by binding to G pro-
tein coupled receptors expressed on the surface of target
cells [6]. The most prominent receptor for CCL2 is CCR2
[7] and its binding to this receptor has been shown to
result in recruitment of monocytes into the subendothe-
lial space [8]. Further evidence for the role of CCL2 and
its receptor CCR2 in the pathology of atherosclerosis has
come from gene knock-out experiments in mice. CCR2 (-
/-) mice show defects in leukocyte adhesion and mono-
cyte/macrophage recruitment [9]. The absence of CCR2
on macrophages protects those mice from developing
atherosclerosis [10-12]. Moreover, mice lacking the
ligand CCL2 (-/-) also showed decreased lesion size and a
significant reduction of macrophages in lesions [13]. In
addition, overexpression of CCL2 results in an increase in
macrophage number within the lesions [14]. Taken
together, these studies strongly suggest a direct role for
C C L 2  a n d  C C R 2  i n  m o n o cy t e  r e c r u i t m e n t  a n d  i n  t h e
pathology of atherosclerosis. The CCR2 gene comprises
two exons and is subject to alternative splicing [6]. A G to
A coding polymorphism in exon 2 of the gene has been
reported which results in a Val to Ile substitution at posi-
tion 64. Evidence for this polymorphism having an effect
on the function of CCR2 comes from studies of HIV
infected individuals. CCR2 and CCR5 are required for
the entry of the virus into lymphocytes. Those individuals
carrying the CCR2 Ile allele were found to progress to
AIDS 2-4 years later than individuals homozygous for the
common Val allele [15]. We and others have reported on
the role of this polymorphism in the development of cor-
onary artery disease, but the findings do not all appear to
be in agreement. In our previous study [16] we looked at
the effect of the V al64Ile polymorphism in a cohort of
first degree relatives of patients with premature coronary
artery disease. The extent of coronary artery calcification
was found to be significantly lower in subjects with the
CCR2 Ile64 variant than in subjects carrying two Val64
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alleles which we interpreted as being beneficial. A similar
conclusion was drawn by Szalai et. al. [17] based on the
absence of any CCR2 Ile64 homozygotes in the cases
group of a CAD case-control study. In contrast, Ortlepp
et. al. [18] found the Ile64 allele to be associated with an
increased risk for MI (myocardial infarction) and heart
failure in subjects of age <65 y in a large cohort of patients
who underwent left ventricular catheterization and also
Gonzalez  et. al.  [ 1 9 ]  w e r e  u n a b l e  t o  f i n d  a  p r o t e c t i v e
effect of the Ile64 allele MI in a case control study. To
investigate further our previous suggestion for a protec-
tive effect of Ile64 in coronary atherosclerosis, we exam-
ined the role of the V al64Ile polymorphism in a nested
case-control sample from the West of Scotland Coronary
Prevention (WOSCOPS) study.
Methods
Woscops
The West of Scotland Coronary prevention study
(WOSCOPS) was a randomised, double-blind, placebo
controlled trial of pravastatin [20]. The aim of the study
was to examine the effect of pravastatin in preventing
non fatal MI or death from coronary artery disease. A
total of 6595 men aged 45-64 years (mean 55.2 years)
with raised cholesterol levels were randomised in equal
numbers to pravastatin after initial screening of approxi-
mately 81,000 subjects. Individuals had no history of
myocardial infarction and had normal renal and hepatic
function. Cases were defined as those individuals who,
during the course of the five year study, died from definite
coronary artery disease (CAD) or who experienced non-
fatal acute myocardial infarction, or who were subject to
re-vascularisation. Controls, also taken from the original
cohort of 6595 men with raised cholesterol levels, did not
have a cardiac event. Each case was matched with 2 con-
trols on the basis of age and smoking status. In this pres-
ent study 443 cases and 1003 controls were examined
where specimens had been stored for genetic analysis.
182 of the cases (41%) and 509 controls (51%) received
pravastatin treatment. Ethical approval for the study was
received from each of the four ethical committees in the
west of Scotland (Lanarkshire, Glasgow, Argyle & Clyde
and Dumfries & Galloway). Informed consent for the
present genetics study was received from all individuals.
Val64Ile Genotyping
The samples in this study were genotyped using the
amplifluor genotyping method [21]. Using this method,
two allele specific primers are designed, each of which is
complementary to either the wild type or variant allele of
the polymorphism at the 3' most base of the primer. Each
primer has a 5' tail which enables it to bind to one of two
"uniprimers". A "common" primer is the reverse primer
for the PCR reaction. Each uniprimer is labelled with a
fluorescent dye (JOE or FAM, Applied Biosystems). Dur-
ing the course of the reaction, uniprimers fluoresce if the
SNP (Single Nucleotide Polymorphism) allele is comple-
mentary to the end base of the primer. The Val64Ile poly-
morphism is a G to A polymorphism situated in exon 2 of
the b isoform of CCR2. The presence of a high fluores-
cence signal for FAM indicates a G/G genotype, a high
level of JOE fluorescence indicates an A/A genotype.
Intermediate levels of FAM and JOE fluorescence indi-
cate a heterozygous G/A genotype. The fluorescence
measurements were carried out using an ABI 7700
sequence detection system (Applied Biosystems).
The primer sequences used were as follows:
Allele 1 G GAAGGTGACCAAGTTCATGCTTTTG-
CAGTTTATTAAGATGAGGAC
Table 1: CCR2 Val64Ile genotypes and allele frequencies for cases and controls.
Phenotype and 
Genotype
Cases (n = 443)
(frequency %)
Controls 
(n = 1003)
(frequency %)
Odds Ratio
(Ile/Ile or Val/Ile)
95% confidence 
interval
P-value
Death/Non-fatal 
event
Val/Val 384 (86.7) 884 (88.1)
Val/Ile or Ile/Ile 
(pooled)
59 (13.3) 119 (11.9) 1.15 0.82 - 1.61 0.410
Val 0.93 0.94
Ile 0.07 0.06Dow et al. BMC Research Notes 2010, 3:31
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Allele 2 A GAAGGTCGGAGTCAACGGATTTTTG-
CAGTTTATTAAGATGAGGAT
Common 1 GCTCTACTCGCTGGTGTTCAT
The PCR product size was 74 bp.
Statistical analysis
The WOSCOPS Biobank is a generic tool designed for
various case-control studies. The power of the design
depends on the gene frequency of the genotype being
studied. A case-control study with 443 cases and 1003
controls can detect with 80% power a rate-ratio of 1.71
for a gene frequency of 5%, a rate-ratio of 1.50 for a gene
frequency of 10%, and a rate-ratio of 1.42 for a gene fre-
quency of 15%. A chi-squared analysis was used to deter-
mine if the distribution of genotypes was in Hardy-
Weinberg equilibrium. Conditional logistic regression
was used to assess the effect of individual alleles by calcu-
lating odds ratios with associated 95% confidence inter-
val.
Results
Study subjects
The CCR2 Val64Ile genotype was determined in a total of
443 cases and 1003 control individuals from the
WOSCOPS sample set. The CCR2 polymorphism was
found to be in Hardy-Weinberg equilibrium (Cases: chi-
squared = 2.25, p = 0.13; Controls: chi-squared = 0.02, p =
0.9). Genotype frequencies were as follows: Val/Val 1268
(87.7%), Val/Ile 174 (12%) and Ile/Ile 4 (0.3%). This gave a
minor allele frequency for the Ile allele of 0.06. Due to the
small number of Ile/Ile homozygotes, we pooled
heterozygotes and homozygotes for the minor allele prior
to analysis. Table 1 shows the results of statistical analy-
sis. For the clinical endpoint of death from definite coro-
nary artery disease (CAD), non-fatal acute myocardial
infarction, or a re-vascularisation event, the odds ratio for
the Ile allele was 1.15 (95% CI 0.82 - 1.61).
In addition, the analysis of the re-vascularisation end
point only produced an odds ratio of 0.78 (95% CI 0.33 -
1.87), the odds ratio for the non-fatal acute myocardial
infarction endpoint was 1.28 (95% CI 0.89 - 1.86) and for
the death from definite coronary artery disease (CAD)
endpoint it was 0.96 (95% CI 0.45 - 2.08). All three sub-
group analyses were non-significant.
Discussion
For a complex pathology such as coronary artery disease,
there are likely to be many susceptibility genes which play
a role in determining the phenotype [22]. Based upon
previous work implicating the CCR2 gene in the progres-
sion of atherosclerosis, we sought to further assess the
role of the Val64Ile polymorphism in the clinical end-
point of coronary artery disease. In this study we exam-
ined the genotypes of 443 cases and 1003 control
individuals from the WOSCOPS study. The results
obtained for both the combined and single endpoint anal-
yses did not indicate a significant difference in genotype
frequencies between cases and controls and so do not
suggest a significant role for this polymorphism in the
development of coronary artery disease. A number of
recent studies have looked at the association of the CCR2
Val64Ile polymorphism and clinical endpoints associated
with atherosclerosis. In our previous study the extent of
coronary artery calcification was significantly lower in
subjects with the CCR2 Ile64 variant than in subjects car-
rying two Val64 alleles [16] suggesting a beneficial effect
for the Ile64 allele. Coronary artery calcification has pre-
viously been shown to be correlated with the extent of
coronary atherosclerotic lesions [23]. The results of our
present study are not in agreement with our previous
study and there are several potential explanations for this.
Firstly the definition of cases was different. Valdes et al.
defined cases as male or female first degree relatives of
subjects with premature coronary artery disease and
there were various exclusion criteria including smoking
status. Subjects were non-Hispanic whites from the
Pennsylvania area. In the Woscops study, all subjects
were men from the west of Scotland with pre-determined
cut off values for cholesterol and LDL/cholesterol and
smokers were included. The phenotypes are also different
between the studies. Valdes et al. measured coronary
artery calcification (CAC) using tomography. In Woscops
the endpoints were death from coronary artery disease
(CAD), non-fatal acute myocardial infarction, or re-vas-
cularisation. In addition the sam ple sets were different
with 400 cases and 1003 controls for this study and 662
subjects in the CAC study. In Valdes et al, the genotype
frequencies were compared between individuals in a high
or low CAC value group whereas the cases in Woscops
were those with the aforementioned endpoints. Also in
Woscops, each case was matched to 2 controls. It is possi-
ble that these differences in study design or geographical
location of subjects could account for the different con-
clusions from the two studies examining the same Val64
Ile polymorphism. Other evidence attributing a role for
CCR2 in the development of atherosclerosis has been
shown [18]. In contrast, here the Ile allele was found to be
positively associated with myocardial infarction and
heart failure in patients less than 65 years of age. There
was no association of the CCR2 genotype with athero-
sclerosis, but the CCR2 Ile allele appeared to predispose
patients to myocardial infarction before 65 years of age.
In other work, the role of CCR2 Val64Ile was not sup-
ported in studies of both myocardial infarction and coro-
nary artery disease as diagnosed by angiography in
patients versus controls [19,24]. Also recently Bjarnadot-
tir et al. [25] were unable to find any effect of the CCR2
Val64Ile mutation in a large Icelandic retrospectiveDow et al. BMC Research Notes 2010, 3:31
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nested case-control study of MI survivors. Again it can-
not be excluded that the different conclusions of these
studies could be related to differences in study design,
clinical endpoints of the coronary artery disease pheno-
type or that subjects were derived from different geo-
graphical populations where there are differences in
genetic or environmental factors [26]. The WOSCOPS
sample set is a large, well characterised cohort compris-
ing individuals from the same geographical location. In
summary, the results of this present study do not support
a role for the CCR2Val64Ile polymorphism in the end-
points of death from coronary artery disease (CAD), non-
fatal acute myocardial infarction, or re-vascularisation.
Conclusions
This CCR2 association study does not confirm a role for
the CCR2 Val64Ile polymorphism in the development of
coronary artery disease.
Competing interests
DJD is an employee of GlaxoSmithKline. ICG and PHEG are former employees
of GlaxoSmithKline.
Authors' contributions
DJD - Designed, planned and managed the CCR2 study, designed genotyping
assays and wrote the manuscript. ADM - Designed the CCR2 study, preformed
statistical analysis of the genotyping data and edited the manuscript. ICG -
Designed the CCR2 study and edited the manuscript. CJP - Advised on the
study, is a main investigator of the WOSCOPS study and edited the manuscript.
PHEG - managed the study and edited the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The polymorphism work described was funded by GlaxoSmithKline.
Author Details
1GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, 
SG1 2NY, UK, 
2Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, 
G12 8QQ, UK, 
3Division of Medical Sciences, University of Glasgow, Western Infirmary, 
Glasgow, G11 6NT, UK and 
4Current Address: Takeda Singapore, 10 Biopolis Road, 03-01/02 Chromas, 
138670, Singapore
References
1. Ross R: Atherosclerosis--an inflammatory disease.  N Engl J Med 1999, 
340:115-126.
2. Bursill CA, Channon KM, Greaves DR: The role of chemokines in 
atherosclerosis: recent evidence from experimental models and 
population genetics.  Curr Opin Lipidol 2004, 15:145-149.
3. Gautier EL, Jakubzick C, Randolph GJ: Regulation of the migration and 
survival of monocyte subsets by chemokine receptors and its 
relevance to atherosclerosis.  Arterioscler Thromb Vasc Biol 2009, 
29:1412-1418.
4. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al.: 
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to 
accumulate within atherosclerotic plaques.  J Clin Invest 2007, 
117:185-194.
5. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte 
chemoattractant protein-1 in human atheromatous plaques.  J Clin 
Invest 1991, 88:1121-1127.
6. Horuk R: Molecular properties of the chemokine receptor family.  Trends 
Pharmacol Sci 1994, 15:159-165.
7. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR: 
Molecular cloning and functional expression of two monocyte 
chemoattractant protein 1 receptors reveals alternative splicing of the 
carboxyl-terminal tails.  Proc Natl Acad Sci USA 1994, 91:2752-2756.
8. Weber C: Novel mechanistic concepts for the control of leukocyte 
transmigration: specialization of integrins, chemokines, and junctional 
molecules.  J Mol Med 2003, 81:4-19.
9. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, et al.: 
Severe reduction in leukocyte adhesion and monocyte extravasation 
in mice deficient in CC chemokine receptor 2.  Proc Natl Acad Sci USA 
1997, 94:12053-12058.
10. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, et 
al.: Impaired monocyte migration and reduced type 1 (Th1) cytokine 
responses in C-C chemokine receptor 2 knockout mice.  J Clin Invest 
1997, 100:2552-2561.
11. Dawson TC, Kuziel WA, Osahar TA, Maeda N: Absence of CC chemokine 
receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice.  
Atherosclerosis 1999, 143:205-211.
12. Guo J, Van Eck M, Twisk J, Maeda N, Benson GM, Groot PH, et al.: 
Transplantation of monocyte CC-chemokine receptor 2-deficient bone 
marrow into ApoE3-Leiden mice inhibits atherogenesis.  Arterioscler 
Thromb Vasc Biol 2003, 23:447-453.
13. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al.: Absence 
of monocyte chemoattractant protein-1 reduces atherosclerosis in low 
density lipoprotein receptor-deficient mice.  Mol Cell 1998, 2:275-281.
14. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, et al.: 
Monocyte chemoattractant protein-1 accelerates atherosclerosis in 
apolipoprotein E-deficient mice.  Arterioscler Thromb Vasc Biol 1999, 
19:1518-1525.
15. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al.: 
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 
infection and disease progression. Hemophilia Growth and 
Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), 
Multicenter Hemophilia Cohort Study (MHCS), San Francisco City 
Cohort (SFCC), ALIVE Study.  Science 1997, 277:959-965.
16. Valdes AM, Wolfe ML, O'Brien EJ, Spurr NK, Gefter W, Rut A, et al.: Val64Ile 
polymorphism in the C-C chemokine receptor 2 is associated with 
reduced coronary artery calcification.  Arterioscler Thromb Vasc Biol 2002, 
22:1924-1928.
17. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al.: 
Involvement of polymorphisms in the chemokine system in the 
susceptibility for coronary artery disease (CAD). Coincidence of 
elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients.  
Atherosclerosis 2001, 158:233-239.
18. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, et al.: 
Chemokine receptor (CCR2) genotype is associated with myocardial 
infarction and heart failure in patients under 65 years of age.  J Mol Med 
2003, 81:363-367.
19. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, et al.: 
Genetic variation at the chemokine receptors CCR5/CCR2 in 
myocardial infarction.  Genes Immun 2001, 2:191-195.
20. Screening experience and baseline characteristics in the West of 
Scotland Coronary Prevention Study. The WOSCOPS Study Group. 
West of Scotland Coronary Prevention Study.  Am J Cardiol 1995, 
76:485-491.
21. Khripin Y: High-throughput genotyping with energy transfer-labeled 
primers.  Methods Mol Biol 2006, 335:215-240.
22. Lusis AJ: Genetic factors in cardiovascular disease. 10 questions.  Trends 
Cardiovasc Med 2003, 13:309-316.
23. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS: 
Coronary artery calcium area by electron-beam computed 
tomography and coronary atherosclerotic plaque area. A 
histopathologic correlative study.  Circulation 1995, 92:2157-2162.
24. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D, 
Spandidos DA: Effects of polymorphisms in chemokine ligands and 
receptors on susceptibility to coronary artery disease.  Thromb Res 
2007, 119:63-71.
25. Bjarnadottir K, Eiriksdottir G, Aspelund T, Gudnason V: Examination of 
genetic effects of polymorphisms in the MCP-1 and CCR2 genes on MI 
in the Icelandic population.  Atherosclerosis 2006, 188:341-346.
Received: 14 September 2009 Accepted: 2 February 2010 
Published: 2 February 2010
This article is available from: http://www.biomedcentral.com/1756-0500/3/31 © 2010 Dow et al; licensee BioMed Central Ltd.  This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Research Notes 2010, 3:31Dow et al. BMC Research Notes 2010, 3:31
http://www.biomedcentral.com/1756-0500/3/31
Page 5 of 5
26. Kathiresan S, Newton-Cheh C, Gerszten RE: On the interpretation of 
genetic association studies.  Eur Heart J 2004, 25:1378-1381.
doi: 10.1186/1756-0500-3-31
Cite this article as: Dow et al., CCR2 and coronary artery disease: a woscops 
substudy BMC Research Notes 2010, 3:31